Syndax Pharmaceuticals, Inc. (SNDX) Guidance & Earnings Results
On 2026-01-12 Syndax Pharmaceuticals, Inc. reaffirmed guidance: "2026 R&D+SG&A ~$400M; expects…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SNDXSyndax Pharmaceuticals, Inc.Follow SNDX — free
—
Price chart with a free account
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Jan 26 | Reaffirmed | 2026 R&D+SG&A ~$400M; expects profitability. · full year |
Syndax Pharmaceuticals, Inc. — questions
- What guidance did Syndax Pharmaceuticals, Inc. give?
- On 2026-01-12: "2026 R&D+SG&A ~$400M; expects profitability."
- When does Syndax Pharmaceuticals, Inc. report earnings?
- Syndax Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Syndax Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.